Belite Bio (BLTE) said Wednesday the US Food and Drug Administration granted breakthrough therapy designation to its Tinlarebant drug for treating Stargardt disease.
The company said the decision is based on early results from an ongoing phase 3 trial, which showed that the drug may significantly improve over current treatment options.
The designation expedites the development and regulatory review of drugs that are intended for serious or life-threatening conditions, Belite Bio said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.